Vertex Pharmaceuticals Inc (NASDAQ:VRTX) — Market Cap & Net Worth
Market Cap & Net Worth: Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a market capitalization of $130.90 Billion ($130.90 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #186 globally and #101 in its home market, demonstrating a -6.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vertex Pharmaceuticals Inc's stock price $519.51 by its total outstanding shares 253460924 (253.46 Million). Also see Vertex Pharmaceuticals Inc (VRTX) total assets for a full breakdown of the balance sheet.
Vertex Pharmaceuticals Inc Market Cap History: 2015 to 2026
Vertex Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $31.89 Billion to $131.68 Billion (14.74% CAGR). Also see Vertex Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Vertex Pharmaceuticals Inc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 12.36% | #3 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 11.24% | #4 of 39 |
|
S&P 500 Index
GSPC
|
$63.09 Trillion | 0.27% | #82 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 4.89% | #5 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.31% | #37 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 6.93% | #4 of 263 |
|
Nasdaq 100
NDX
|
$35.22 Trillion | 0.37% | #34 of 101 |
Weight: Vertex Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vertex Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vertex Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Vertex Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
9.52x
Vertex Pharmaceuticals Inc's market cap is 9.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.07x
Vertex Pharmaceuticals Inc's market cap is 29.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $18.67 Billion | $1.70 Billion | -$112.05 Million | 10.97x | N/A |
| 2017 | $37.98 Billion | $2.49 Billion | $263.48 Million | 15.26x | 144.16x |
| 2018 | $42.00 Billion | $3.05 Billion | $2.10 Billion | 13.78x | 20.03x |
| 2019 | $55.50 Billion | $4.16 Billion | $1.18 Billion | 13.33x | 47.16x |
| 2020 | $59.90 Billion | $6.21 Billion | $2.71 Billion | 9.65x | 22.09x |
| 2021 | $55.66 Billion | $7.57 Billion | $2.34 Billion | 7.35x | 23.77x |
| 2022 | $73.19 Billion | $8.93 Billion | $3.32 Billion | 8.20x | 22.03x |
| 2023 | $103.13 Billion | $9.87 Billion | $3.62 Billion | 10.45x | 28.49x |
| 2024 | $102.07 Billion | $11.02 Billion | -$535.60 Million | 9.26x | N/A |
| 2025 | $114.91 Billion | $12.07 Billion | $3.95 Billion | 9.52x | 29.07x |
Competitor Companies of VRTX by Market Capitalization
Companies near Vertex Pharmaceuticals Inc in the global market cap rankings as of September 15, 2026. Review VRTX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Vertex Pharmaceuticals Inc by market ranking:
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.46 Billion USD ( €40.60 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
| #573 | Argen-X | BR:ARGX | $47.46 Billion | €867.80 |
Vertex Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Vertex Pharmaceuticals Inc's market cap moved from $31.89 Billion to $ 131.68 Billion, with a yearly change of 14.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $131.68 Billion | +14.59% |
| 2025 | $114.91 Billion | +12.58% |
| 2024 | $102.07 Billion | -1.03% |
| 2023 | $103.13 Billion | +40.90% |
| 2022 | $73.19 Billion | +31.50% |
| 2021 | $55.66 Billion | -7.08% |
| 2020 | $59.90 Billion | +7.94% |
| 2019 | $55.50 Billion | +32.13% |
| 2018 | $42.00 Billion | +10.58% |
| 2017 | $37.98 Billion | +103.42% |
| 2016 | $18.67 Billion | -41.45% |
| 2015 | $31.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Vertex Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $130.90 Billion USD |
| MoneyControl | $130.90 Billion USD |
| MarketWatch | $130.90 Billion USD |
| marketcap.company | $130.90 Billion USD |
| Reuters | $130.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more